Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt

Hypertension

Volumn 57, Issue 2, 2011, Pages 238-244

  Griol Charhbili, Violaine ^a,b   Fassot, Céline ^a,b   Messaoudi, Smail ^a,b   Perret, Claudine ^a,b   Agrapart, Vincent ^a,b   Jaisser, Frederic ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

cross talk; EGFR deficiency; in vivo; mineralocorticoid; vascular

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; EPIDERMAL GROWTH FACTOR RECEPTOR; PHENYLEPHRINE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; IN VIVO STUDY; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROVOCATION TEST; VASCULAR DISEASE; VASOCONSTRICTION;

ACETYLCHOLINE; ALDOSTERONE; ANGIOTENSIN II; ANIMALS; AORTA; BLOTTING, WESTERN; CAROTID ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENOTYPE; HEMODYNAMICS; MALE; MICE; MICE, MUTANT STRAINS; NADPH OXIDASE; NEPHRECTOMY; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; PHENYLEPHRINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 79551487567     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.153619     Document Type: Article

References (42)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709-717.
3. Funder JW. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs. 2007;7:151-157.
4. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010;24:2454-2463.
5. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312-318.
6. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR. 11/3-Hydroxysteroid dehydrogenase type 2 in mouse aorta: Localization and influence on response to glucocorticoids. Hypertension. 2003;42: 580-587.
7. Smith RE, Little PJ, Maguire JA, Stein-Oakley AN, Krozowski ZS. Vascular localization of the 11 /3-hydroxysteroid dehydrogenase type ii enzyme. Clin Exp Pharmacol Physiol. 1996;23:549-551.
8. Cachofeiro V, Miana M, de Las Heras N, Martin-Fernandez B, Ball-esteros S, Fernandez-Tresguerres J, Lahera V. Aldosterone and the vascular system. J Steroid Biochem Mol Biol. 2008;109:331-335.
9. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007; 13:189-197.
10. Muiesan ML, Rizzoni D, Salvetti M, Porteri E, Monteduro C, Guelfi D, Castellano M, Garavelli G, Agabiti-Rosei E. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens. 2002;20:1439-1444.
11. Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch. 2009;458: 231-246.
12. Grossmann C, Gekle M. Non-classical actions of the mineralocorticoid receptor: misuse of EGF receptors? Mol Cell Endocrinol. 2007;277:6-12.
13. Florian JA, Dorrance A, Webb RC, Watts SW. Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am J Physiol Regul Integr Comp Physiol. 2001;281:R878-R886.
14. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19:1697-1710.
15. Krug AW, Grossmann C, Schuster C, Freudinger R, Mildenberger S, Govindan MV, Gekle M. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem. 2003;278:43060-43066.
16. Gekle M, Mildenberger S, Freudinger R, Grossmann C. Altered collagen homeostasis in human aortic smooth muscle cells (HaoSMCs) induced by aldosterone. Pflugers Arch. 2007;454:403-413.
17. Fowler KJ, Walker F, Alexander W, Hibbs ML, Nice EC, Bohmer RM, Mann GB, Thumwood C, Maglitto R, Danks JA, Chetty R, Burgess AW, Dunn AR. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc Natl Acad Sci USA. 1995;92:1465-1469.
18. Luetteke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, Jenkins NA, Lee DC. The mouse waved-2 phenotype results from a point mutation in the egf receptor tyrosine kinase. Genes Dev. 1994;8:399-413.
19. Loufrani L, Matrougui K, Gorny D, Duriez M, Blanc I, Levy BI, Henrion D. Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation. 2001;103: 864-870.
20. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97.
21. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008; 51:161-167.
22. Montezano AC, Touyz RM. Networking between systemic angiotensin ii and cardiac mineralocorticoid receptors. Hypertension. 2008;52: 1016-1018.
23. Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and en-dothelial function. Curr Opin Investig Drugs. 2008;9:963-969.
24. Perry PA, Webb RC. Sensitivity and adrenoceptor affinity in the mes-enteric artery of the deoxycorticosterone acetate hypertensive rat. Can J Physiol Pharmacol. 1988;66:1095-1099.
25. Couture R, Regoli D. Vascular reactivity to angiotensin and noradrenaline in rats maintained on a sodium free diet or made hypertensive with desoxycorticosterone acetate and salt (doca/salt). Clin Exp Hypertens. 1980;2:25-43.
26. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800.
27. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin ii synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res. 2005;97:434-442.
28. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96:643-650.
29. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-src-regulated redox-sensitive rhoa pathways. Arterioscler Thromb Vasc Biol. 2008;28: 1511-1518.
30. Miyata K, Hitomi H, Guo P, Zhang GX, Kimura S, Kiyomoto H, Hosomi N, Kagami S, Kohno M, Nishiyama A. Possible involvement of rho-kinase in aldosterone-induced vascular smooth muscle cell remodeling. Hypertens Res. 2008;31:1407-1413.
31. Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Aldosterone interaction with epidermal growth factor receptor signaling in mdck cells. Am J Physiol Renal Physiol. 2002;282:F669-F679.
32. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation. 2002;106:2848-2853.
33. Nehme J, Mercier N, Labat C, Benetos A, Safar ME, Delcayre C, Lacolley P. Differences between cardiac and arterial fibrosis and stiffness in aldoste-rone-salt rats: effect of eplerenone. J Renin Angiotensin Aldosterone Syst. 2006;7:31-39.
34. Nagareddy PR, MacLeod KM, McNeill JH. Gpcr agonist-induced trans-activation of the egfr upregulates mlc II expression and promotes hypertension in insulin-resistant rats. Cardiovasc Res. 87:177-186.
35. Montiel M, de la Blanca EP, Jimenez E. Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2005; 327:971-978.
36. Sugiyama T, Yoshimoto T, Tsuchiya K, Gochou N, Hirono Y, Tateno T, Fukai N, Shichiri M, Hirata Y. Aldosterone induces angiotensin converting enzyme gene expression via a jak2-dependent pathway in rat endothelial cells. Endocrinology. 2005;146:3900-3906.
37. Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res. 2009;82:261-271.
38. Wehrwein EA, Northcott CA, Loberg RD, Watts SW. Rho/rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther. 2004;309:1011-1019.
39. Mehta VB, Besner GE. Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced nf-kappa b activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway. J Immunol. 2005;175:1911-1918.
40. Chansel D, Ciroldi M, Vandermeersch S, Jackson LF, Gomez AM, Henrion D, Lee DC, Coffman TM, Richard S, Dussaule JC, Tharaux PL. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J. 2006;20:1936-1938.
41. Zahorowska B, Crowe PJ, Yang JL. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol. 2009;135:1137-1148.
42. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-her-2 therapies: what have we learned so far? Target Oncol. 2009;4:77-88.